Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Nov;39(11):2478–2483. doi: 10.1128/aac.39.11.2478

Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli.

P Stapleton 1, P J Wu 1, A King 1, K Shannon 1, G French 1, I Phillips 1
PMCID: PMC162968  PMID: 8585729

Abstract

Among Escherichia coli organisms isolated at St. Thomas's Hospital during the years 1990 to 1994, the frequency of resistance to amoxicillin-clavulanic acid (tested by disk diffusion in a ratio of 2:1) remained constant at about 5% of patient isolates (10 to 15% of the 41 to 45% that were amoxicillin resistant). Mechanisms of increased resistance were determined for 72 consecutively collected such amoxicillin-clavulanic acid-resistant isolates. MICs of the combination were 16-8 micrograms/ml for 51 (71%) of these and > or = 32-16 micrograms/ml for the remainder. The predominant mechanism was hyperproduction of enzymes isoelectrically cofocusing with TEM-1 (beta-lactamase activities, > 200 nmol of nitrocefin hydrolyzed per min per mg of protein) which was found in 44 isolates (61%); two isolates produced smaller amounts (approximately 150 nmol/min/mg) of such enzymes, and two isolates hyperproduced enzymes cofocusing with TEM-2. Eleven isolates produced enzymes cofocusing with OXA-1 beta-lactamase, which has previously been associated with resistance to amoxicillin-clavulanic acid. Ten isolates produced increased amounts of chromosomal beta-lactamase, and four of these additionally produced TEM-1 or TEM-2. Three isolates produced inhibitor-resistant TEM-group enzymes. In one of the enzymes (pI, 5.4), the amino acid sequence change was Met-67-->Val, and thus the enzyme is identical to TEM-34. Another (pI, 5.4) had the substitution Met-67-->Ile and is identical to IRT-I67, which we propose now be given the designation TEM-40. The third (pI, 5.2) had the substitution Arg-241-->Thr; this enzyme has not been reported previously and should be called TEM-41. The rarity and diversity of inhibitor-resistant TEM-group enzymes suggest that they are the result of spontaneous mutations that have not yet spread.

Full Text

The Full Text of this article is available as a PDF (293.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alós J. I., Gómez-Garcés J. L., García-Bermejo I., García-Gómez J. J., González-Palacios R., Padilla B. Prevalencia de susceptibilidad de Escherichia coli a quinolonas y otros antibióticos en bacteriurias extrahospitalarias de Madrid. Med Clin (Barc) 1993 Jun 12;101(3):87–90. [PubMed] [Google Scholar]
  2. Ambler R. P., Coulson A. F., Frère J. M., Ghuysen J. M., Joris B., Forsman M., Levesque R. C., Tiraby G., Waley S. G. A standard numbering scheme for the class A beta-lactamases. Biochem J. 1991 May 15;276(Pt 1):269–270. doi: 10.1042/bj2760269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aubert G., Peyle V., Dumont N., el Fassi M., Dorche G. Emergence d'une souche d'Escherichia coli hyperproductrice de céphalosporinase au cours d'un traitement par l'association amoxicilline plus acide clavulanique. Ann Biol Clin (Paris) 1990;48(7):449–454. [PubMed] [Google Scholar]
  4. Blazquez J., Baquero M. R., Canton R., Alos I., Baquero F. Characterization of a new TEM-type beta-lactamase resistant to clavulanate, sulbactam, and tazobactam in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother. 1993 Oct;37(10):2059–2063. doi: 10.1128/aac.37.10.2059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brun T., Péduzzi J., Caniça M. M., Paul G., Névot P., Barthélémy M., Labia R. Characterization and amino acid sequence of IRT-4, a novel TEM-type enzyme with a decreased susceptibility to beta-lactamase inhibitors. FEMS Microbiol Lett. 1994 Jul 1;120(1-2):111–117. doi: 10.1111/j.1574-6968.1994.tb07016.x. [DOI] [PubMed] [Google Scholar]
  6. Bush K. Characterization of beta-lactamases. Antimicrob Agents Chemother. 1989 Mar;33(3):259–263. doi: 10.1128/aac.33.3.259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. French G., Ling T. Amoxycillin/clavulanate resistant Escherichia coli. Lancet. 1988 Mar 26;1(8587):704–704. doi: 10.1016/s0140-6736(88)91500-0. [DOI] [PubMed] [Google Scholar]
  8. Henquell C., Chanal C., Sirot D., Labia R., Sirot J. Molecular characterization of nine different types of mutants among 107 inhibitor-resistant TEM beta-lactamases from clinical isolates of Escherichia coli. Antimicrob Agents Chemother. 1995 Feb;39(2):427–430. doi: 10.1128/aac.39.2.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Henquell C., Sirot D., Chanal C., De Champs C., Chatron P., Lafeuille B., Texier P., Sirot J., Cluzel R. Frequency of inhibitor-resistant TEM beta-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother. 1994 Nov;34(5):707–714. doi: 10.1093/jac/34.5.707. [DOI] [PubMed] [Google Scholar]
  10. Hoban D. J., Jones R. N., Harrell L. J., Knudson M., Sewell D. The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance. Diagn Microbiol Infect Dis. 1993 Aug-Sep;17(2):157–161. doi: 10.1016/0732-8893(93)90027-5. [DOI] [PubMed] [Google Scholar]
  11. Hunter J. E., Corkill J. E., McLennan A. G., Fletcher J. N., Hart C. A. Plasmid encoded beta-lactamases resistant to inhibition by clavulanic acid produced by calf faecal coliforms. Res Vet Sci. 1993 Nov;55(3):367–370. doi: 10.1016/0034-5288(93)90109-s. [DOI] [PubMed] [Google Scholar]
  12. Ling T. K., Lyon D. J., Cheng A. F., French G. L. In-vitro antimicrobial susceptibility and beta-lactamases of ampicillin-resistant Escherichia coli in Hong Kong. J Antimicrob Chemother. 1994 Jul;34(1):65–71. doi: 10.1093/jac/34.1.65. [DOI] [PubMed] [Google Scholar]
  13. Marre R., Schulz E. In vitro activity of mecillinam and amoxicillin/clavulanic acid against strains of Escherichia coli producing TEM-1, Oxa-1 and chromosomal beta-lactamases. Arzneimittelforschung. 1988 Jul;38(7):863–865. [PubMed] [Google Scholar]
  14. Martin M. A., Pfaller M. A., Rojas P. B., Woolson R. F., Wenzel R. P. In-vitro susceptibility of nosocomial gram-negative bloodstream pathogens to quinolones and other antibiotics--a statistical approach. J Antimicrob Chemother. 1989 Mar;23(3):353–361. doi: 10.1093/jac/23.3.353. [DOI] [PubMed] [Google Scholar]
  15. Oliphant A. R., Struhl K. An efficient method for generating proteins with altered enzymatic properties: application to beta-lactamase. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9094–9098. doi: 10.1073/pnas.86.23.9094. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Reading C., Cole M. Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus. Antimicrob Agents Chemother. 1977 May;11(5):852–857. doi: 10.1128/aac.11.5.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Reguera J. A., Baquero F., Perez-Diaz J. C., Martinez J. L. Synergistic effect of dosage and bacterial inoculum in TEM-1 mediated antibiotic resistance. Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):778–779. doi: 10.1007/BF01975047. [DOI] [PubMed] [Google Scholar]
  18. Reguera J. A., Baquero F., Pérez-Díaz J. C., Martínez J. L. Factors determining resistance to beta-lactam combined with beta-lactamase inhibitors in Escherichia coli. J Antimicrob Chemother. 1991 May;27(5):569–575. doi: 10.1093/jac/27.5.569. [DOI] [PubMed] [Google Scholar]
  19. Roy C., Segura C., Torrellas A., Reig R., Teruel D., Hermida M. Activity of amoxycillin/clavulanate against beta-lactamase-producing Escherichia coli and Klebsiella spp. J Antimicrob Chemother. 1989 Nov;24 (Suppl B):41–47. doi: 10.1093/jac/24.suppl_b.41. [DOI] [PubMed] [Google Scholar]
  20. Sanders C. C., Iaconis J. P., Bodey G. P., Samonis G. Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests. Antimicrob Agents Chemother. 1988 Sep;32(9):1365–1369. doi: 10.1128/aac.32.9.1365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Seetulsingh P. S., Hall L. M., Livermore D. M. Activity of clavulanate combinations against TEM-1 beta-lactamase-producing Escherichia coli isolates obtained in 1982 and 1989. J Antimicrob Chemother. 1991 Jun;27(6):749–759. doi: 10.1093/jac/27.6.749. [DOI] [PubMed] [Google Scholar]
  22. Shannon K., King A., Phillips I. Prevalence of resistance to beta-lactam antibiotics in Escherichia coli isolated from blood from 1969-1991. J Antimicrob Chemother. 1992 Nov;30(5):661–672. doi: 10.1093/jac/30.5.661. [DOI] [PubMed] [Google Scholar]
  23. Shannon K., Williams H., King A., Phillips I. Hyperproduction of TEM-1 beta-lactamase in clinical isolates of Escherichia coli serotype O15. FEMS Microbiol Lett. 1990 Feb;55(3):319–323. doi: 10.1016/0378-1097(90)90016-j. [DOI] [PubMed] [Google Scholar]
  24. Sutcliffe J. G. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3737–3741. doi: 10.1073/pnas.75.8.3737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Thomson C. J., Amyes S. G. Selection of variants of the TEM-1 beta-lactamase, encoded by a plasmid of clinical origin, with increased resistance to beta-lactamase inhibitors. J Antimicrob Chemother. 1993 May;31(5):655–664. doi: 10.1093/jac/31.5.655. [DOI] [PubMed] [Google Scholar]
  26. Thomson C. J., Amyes S. G. TRC-1: emergence of a clavulanic acid-resistant TEM beta-lactamase in a clinical strain. FEMS Microbiol Lett. 1992 Mar 1;70(2):113–117. doi: 10.1016/0378-1097(92)90669-f. [DOI] [PubMed] [Google Scholar]
  27. Thomson K. S., Weber D. A., Sanders C. C., Sanders W. E., Jr Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations. Antimicrob Agents Chemother. 1990 Apr;34(4):622–627. doi: 10.1128/aac.34.4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Vedel G., Belaaouaj A., Gilly L., Labia R., Philippon A., Névot P., Paul G. Clinical isolates of Escherichia coli producing TRI beta-lactamases: novel TEM-enzymes conferring resistance to beta-lactamase inhibitors. J Antimicrob Chemother. 1992 Oct;30(4):449–462. doi: 10.1093/jac/30.4.449. [DOI] [PubMed] [Google Scholar]
  29. Wiedemann B., Kliebe C., Kresken M. The epidemiology of beta-lactamases. J Antimicrob Chemother. 1989 Nov;24 (Suppl B):1–22. doi: 10.1093/jac/24.suppl_b.1. [DOI] [PubMed] [Google Scholar]
  30. Wu P. J., Shannon K., Phillips I. Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics. Antimicrob Agents Chemother. 1994 Mar;38(3):494–498. doi: 10.1128/aac.38.3.494. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wu P. J., Shannon K., Phillips I. beta-Lactamases and susceptibility to beta-lactam antibiotics in Escherichia coli. J Antimicrob Chemother. 1992 Dec;30(6):868–871. doi: 10.1093/jac/30.6.868. [DOI] [PubMed] [Google Scholar]
  32. Yourassowsky E., Van der Linden M. P., MacGilavry G. B., Glupczynsky Y. Y a-t-il en Belgique un accroissement de résistance d'Escherichia coli considéré comme bact erie de référence vis-a-vis de l'association amoxicilline/acide clavulanique? Acta Clin Belg. 1992;47(1):15–20. doi: 10.1080/17843286.1992.11718205. [DOI] [PubMed] [Google Scholar]
  33. Zhou X. Y., Bordon F., Sirot D., Kitzis M. D., Gutmann L. Emergence of clinical isolates of Escherichia coli producing TEM-1 derivatives or an OXA-1 beta-lactamase conferring resistance to beta-lactamase inhibitors. Antimicrob Agents Chemother. 1994 May;38(5):1085–1089. doi: 10.1128/aac.38.5.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES